2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.
Christopher E. Dandoy, MD, MSc, a professor at Cincinnati Children’s Hospital, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy (TA-TMA). The primary challenges are diagnosing and identifying TA-TMA in patients.
Dandoy recommends screening for TA-TMA to overcome this issue. Institutions should obtain complete blood counts for the first month in patients following transplant, as well as renal profiles to look at kidney injury on a daily basis. In addition, physicians should look at lactate dehydrogenase, urine, and for signs of schistocytes in the blood. Dandoy concludes they should also monitor blood pressure closely.